Series C preferred stock sold at $1,000.00 per preferred to Seaside 88
By Devika Patel
Knoxville, Tenn., Dec. 27 - NanoViricides, Inc. plans a $2.5 million registered direct offering of 10% series C convertible preferred stock with Seaside 88, LP, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.
The company will sell 2,500 preferreds at $1,000.00 apiece.
The conversion price will be equal to the lesser of 85% of the 10-day daily volume weighted average trading price of the common stock preceding the conversion date or 88% of the volume weighted average trading price for the trading day immediately prior to a conversion date.
Midtown Partners & Co., LLC is the agent.
Proceeds will be used for working capital and general corporate purposes.
NanoViricides is a West Haven, Conn., biopharmaceutical company.
| Issuer: | NanoViricides, Inc.
|
| Issue: | Series C convertible preferred stock
|
| Amount: | $2.5 million
|
| Shares: | 2,500
|
| Price: | $1,000.00
|
| Dividends: | 10%
|
| Warrants: | No
|
| Agent: | Midtown Partners & Co., LLC
|
| Investor: | Seaside 88, LP
|
| Pricing date: | Dec. 27
|
| Stock symbol: | OTCBB: NNVC
|
| Stock price: | $0.48 at close Dec. 26
|
| Market capitalization: | $74.62 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
